On October 2, GENSCRIPT BIO fell 3.03% in regular trading, trading at 43.04 HKD/share, with turnover of approximately 114 million HKD. The decline marks the latest episode of profit-taking following a cumulative rally of nearly 270% since early July.

The current share price remains significantly above JPMorgan's 41 HKD target price, intensifying short-term selling pressure from profit-locked positions. Notably, JPMorgan previously disposed of approximately 33.75 million shares off-exchange at an average price of 32.74 HKD, totaling roughly 1.105 billion HKD, reducing its long position from 7.37% to 5.64% — a clear institutional realization move. Today's pattern mirrors repeated profit-taking episodes observed in late September, when the stock similarly pulled back after breaching the analyst target level.

On the other hand, FMR LLC added 6.846 million shares on September 24 at an average of 40.25 HKD, lifting its stake to 5.26% and triggering a disclosure threshold. Multiple international institutions have crossed the 5% reporting line in recent weeks, reflecting divergent institutional positioning between those taking profits and those building new exposure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)